Jump to content


Congrats to Margaret, Platinum Member with 1,000 posts and 10 Years of Forums Membership!


Pulmonary Fibrosis In Systemic Sclerosis And Dermatomyositis Demonstrates Marked Improvement After Administration Of Mycophenolate Mofetil


  • Please log in to reply
No replies to this topic

#1 Guest_Jude the Grouch_*

Guest_Jude the Grouch_*
  • Guests

Posted 30 August 2007 - 08:44 AM

Pulmonary Fibrosis In Systemic Sclerosis (SSc) And Dermatomyositis (DM) Demonstrates Marked Improvement After Administration Of Mycophenolate Mofetil (MMF/Cellcept). MMF's immunomodulatory and inhibitory effects on fibroblasts and other non-immune cells and a well established low side effect profile with high tolerance make MMF a potential alternative to cyclophosphamide in the treatment of SSc or DM related interstitial lung disease. L. A. Saketkoo THU0315 EULAR 2007. (Also see: Pulmonary Fibrosis and Dermatomyositis)